Instrument Inactif

Communiqués Mylan Inc Nasdaq

Actions

US6285301072

Produits pharmaceutiques

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

22/07	VIATRIS INC. : Goldman Sachs est neutre sur le titre	ZM
14/07	Les actions indiennes reculent, le conflit au Moyen-Orient ravivant les craintes inflationnistes	RE

Communiqués

08/07	Fitch Downgrades Padagis to 'B'; Outlook Stable	AQ
01/07	Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026	PR
29/06	Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy	PR
16/06	Viatris Recognized as One of the 2026 Best Workplaces™ in Canada	AQ
18/05	U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain	PR
07/05	Viatris to Present at the Bank of America Securities 2026 Healthcare Conference	PR
07/05	Viatris : VTRS Q1 2026 Non-GAAP Reconciliations - FINAL	PU
07/05	Viatris : VTRS Q1 2026 Earnings Presentation - FINAL	PU
07/05	Viatris : VTRS Q1 2026 Earnings Infographic - FINAL	PU
07/05	Viatris: Q1 Earnings Snapshot	AQ
07/05	Viatris Reports First-Quarter 2026 Financial Results	PR
05/05	Viatris Announces Quarterly Dividend	PR
04/05	Viatris Announces Chief Financial Officer Transition	PR
01/05	Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting	PR
13/04	Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting	AQ
13/04	Viatris to Report First Quarter 2026 Financial Results on May 7, 2026	PR
10/04	Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting	PR
23/03	Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)	PR
19/03	Viatris : VTRS Investor Event Presentation FINAL (1)	PU
19/03	Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030	PR
26/02	FDA Accepts Viatris Supplemental New Drug Application for MR-141 for the Treatment of Presbyopia	AQ
26/02	Viatris : VTRS Q4 2025 Earnings Presentation FINAL	PU
26/02	Viatris : VTRS Q4 2025 Non GAAP Reconciliations FINAL	PU
26/02	Viatris : VTRS Q4 2025 Earnings Infographic	PU
26/02	Viatris: Q4 Earnings Snapshot	AQ